Cellular microparticles in the pathogenesis of pulmonary hypertension

European Respiratory Journal

Volumn 42, Issue 1, 2013, Pages 272-279

  Amabile, Nicolas ^a,b,c   Guignabert, Christophe ^c,d   Montani, David ^c,d,e   Yeghiazarians, Yerem ^f   Boulanger, Chantal M ^a,b   Humbert, Marc ^c,d,e  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e BICÊTRE HOSPITAL   (France)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD VESSEL TONE; CELL COMMUNICATION; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; HUMAN; INFLAMMATION; LUNG EMBOLISM; MEMBRANE MICROPARTICLE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOGENESIS; PLATELET MICROPARTICLE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CELL-DERIVED MICROPARTICLES; COAGULANTS; DISEASE PROGRESSION; HUMANS; HYPERTENSION, PULMONARY; INFLAMMATION; PHENOTYPE; PROGNOSIS; VASCULAR RESISTANCE;

EID: 84880167040     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00087212     Document Type: Review

References (63)

1. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: Suppl. 12, 13S-24S. (Pubitemid 38759713)
2. Morrell NW, Adnot S, Archer SL, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S20-S31.
3. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2008; 118: 2372-2379. (Pubitemid 351949764)
4. Eddahibi S, Guignabert C, Barlier-Mur AM, et al. Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation 2006; 113: 1857-1864. (Pubitemid 43739397)
5. Xu R, Mao JH. Gene transcriptional networks integrate microenvironmental signals in human breast cancer. Integr Biol (Camb) 2011; 3: 368-374.
6. Diamant M, Tushuizen ME, Sturk A, et al. Cellular microparticles: new players in the field of vascular disease?Eur J Clin Invest 2004; 34: 392-401. (Pubitemid 38859560)
7. Freyssinet JM. Cellular microparticles: what are they bad or good for? J Thromb Haemost 2003; 1: 1655-1662.
8. Amabile N, Rautou PE, Tedgui A, et al. Microparticles: key protagonists in cardiovascular disorders. Semin Thromb Hemost 2010; 36: 907-916.
9. Bakouboula B, Morel O, Faure A, et al. Procoagulant membrane microparticles correlate with the severity of pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 177: 536-543. (Pubitemid 351442193)
10. Amabile N, Heiss C, Real WM, et al. Circulating endothelial microparticle levels predict hemodynamic severity of pulmonary hypertension. Am J Respir Crit Care Med 2008; 177: 1268-1275. (Pubitemid 351860937)
11. Diehl P, Aleker M, Helbing T, et al. Increased platelet, leukocyte and endothelial microparticles predict enhanced coagulation and vascular inflammation in pulmonary hypertension. J Thromb Thrombolysis 2011; 31: 173-179.
12. Dasgupta SK, Abdel-Monem H, Niravath P, et al. Lactadherin and clearance of platelet-derived microvesicles. Blood 2009; 113: 1332-1339.
13. Willekens FL, Werre JM, Kruijt JK, et al. Liver Kupffer cells rapidly remove red blood cell-derived vesicles from the circulation by scavenger receptors. Blood 2005; 105: 2141-2145. (Pubitemid 40731805)
14. Rautou PE, Vion AC, Amabile N, et al. Microparticles, vascular function, and atherothrombosis. Circ Res 2011; 109: 593-606.
15. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004; 109: 159-165. (Pubitemid 38114133)
16. Masri FA, Xu W, Comhair SA, et al. Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2007; 293: L548-L554. (Pubitemid 47358814)
17. Tu L, Dewachter L, Gore B, et al. Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension. Am J Respir Cell Mol Biol 2011; 45: 311-322.
18. Sakao S, Taraseviciene-Stewart L, Lee JD, et al. Initial apoptosis is followed by increased proliferation of apoptosisresistant endothelial cells. FASEB J 2005; 19: 1178-1180. (Pubitemid 40946457)
19. Tu L, De Man FS, Girerd B, et al. A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents. Am J Respir Crit Care Med 2012; 186: 666-676.
20. Guignabert C, Alvira CM, Alastalo TP, et al. Tie2-mediated loss of peroxisome proliferator-activated c in mice causes PDGF receptor-b-dependent pulmonary arterial muscularization. Am J Physiol Lung Cell Mol Physiol 2009; 297: L1082-L1090.
21. Hong KH, Lee YJ, Lee E, et al. Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation 2008; 118: 722-730.
22. Morel O, Toti F, Hugel B, et al. Procoagulant microparticles: disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc Biol 2006; 26: 2594-2604.
23. Tual-Chalot S, Guibert C, Muller B, et al. Circulating microparticles from pulmonary hypertensive rats induce endothelial dysfunction. Am J Respir Crit Care Med 2010; 182: 261-268.
24. Friedman D, Szmuszkovicz J, Rabai M, et al. Systemic endothelial dysfunction in children with idiopathic pulmonary arterial hypertension correlates with disease severity. J Heart Lung Transplant 2012; 31: 642-647.
25. Peled N, Bendayan D, Shitrit D, et al. Peripheral endothelial dysfunction in patients with pulmonary arterial hypertension. Respir Med 2008; 102: 1791-1796.
26. Amabile N, Heiss C, Chang V, et al. Increased CD62e(+) endothelial microparticle levels predict poor outcome in pulmonary hypertension patients. J Heart Lung Transplant 2009; 28: 1081-1086.
27. Nozaki T, Sugiyama S, Koga H, et al. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. J Am Coll Cardiol 2009; 54: 601-608.
28. Nozaki T, Sugiyama S, Sugamura K, et al. Prognostic value of endothelial microparticles in patients with heart failure. Eur J Heart Fail 2010; 12: 1223-1228.
29. Amabile N, Guerin AP, Tedgui A, et al. Predictive value of circulating endothelial microparticles for cardiovascular mortality in end-stage renal failure: a pilot study. Nephrol Dial Transplant 2012; 27: 1873-1880.
30. Amabile N, Boulanger CM. Circulating microparticle levels in patients with coronary artery disease: a new indicator of vulnerability? Eur Heart J 2011; 32: 1958-1960.
31. Price LC, Wort SJ, Perros F, et al. Inflammation in pulmonary arterial hypertension. Chest 2012; 141: 210-221.
32. MacKenzie A, Wilson HL, Kiss-Toth E, et al. Rapid secretion of interleukin-1b by microvesicle shedding. Immunity 2001; 15: 825-835. (Pubitemid 34008509)
33. Nomura S, Tandon NN, Nakamura T, et al. High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis 2001; 158: 277-287. (Pubitemid 32913636)
34. Rautou PE, Leroyer AS, Ramkhelawon B, et al. Microparticles from human atherosclerotic plaques promote endothelial ICAM-1-dependent monocyte adhesion and transendothelial migration. Circ Res 2011; 108: 335-343.
35. Vince RV, McNaughton LR, Taylor L, et al. Release of VCAM-1 associated endothelial microparticles following simulated SCUBA dives. Eur J Appl Physiol 2009; 105: 507-513.
36. Fourcade O, Simon MF, Viode C, et al. Secretory phospholipase A2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells. Cell 1995; 80: 919-927.
37. Mastronardi ML, Mostefai HA, Meziani F, et al. Circulating microparticles from septic shock patients exert differential tissue expression of enzymes related to inflammation and oxidative stress. Crit Care Med 2011; 39: 1739-1748.
38. Densmore JC, Signorino PR, Ou J, et al. Endothelium-derived microparticles induce endothelial dysfunction and acute lung injury. Shock 2006; 26: 464-471. (Pubitemid 44632275)
39. Buesing KL, Densmore JC, Kaul S, et al. Endothelial microparticles induce inflammation in acute lung injury. J Surg Res 2011; 166: 32-39.
40. Pengo V, Lensing AWA, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350: 2257-2264.
41. Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989; 80: 1198-1206. (Pubitemid 19282508)
42. Bjornsson J, Edwards WD. Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clinic Proc 1985; 60: 16-25. (Pubitemid 15199621)
43. Schermuly RT, Ghofrani HA, Wilkins MR, et al. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol 2011; 8: 443-455.
44. White RJ, Meoli DF, Swarthout RF, et al. Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2007; 293: L583-L590. (Pubitemid 47358820)
45. Johnson SR, Granton JT, Mehta S. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Chest 2006; 130: 545-552. (Pubitemid 44267025)
46. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008; 359: 938-949.
47. Muller I, Klocke A, Alex M, et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J 2003; 17: 476-478.
48. Abid Hussein MN, Boing AN, Biro E, et al. Phospholipid composition of in vitro endothelial microparticles and their in vivo thrombogenic properties. Thromb Res 2008; 121: 865-871. (Pubitemid 351491289)
49. Combes V, Simon AC, Grau GE, et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999; 104: 93-102. (Pubitemid 29534349)
50. Satta N, Toti F, Feugeas O, et al. Monocyte vesiculation is a possible mechanism for dissemination of membraneassociated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J Immunol 1994; 153: 3245-3255. (Pubitemid 24292551)
51. Ye R, Ye C, Huang Y, et al. Circulating tissue factor positive microparticles in patients with acute recurrent deep venous thrombosis. Thromb Res 2012; 130: 253-258.
52. Bucciarelli P, Martinelli I, Artoni A, et al. Circulating microparticles and risk of venous thromboembolism. Thromb Res 2012; 129: 591-597.
53. Kearon C. Natural history of venous thromboembolism. Circulation 2003; 107: Suppl. 1, I22-I30. (Pubitemid 41289268)
54. Watts JA, Lee YY, Gellar MA, et al. Proteomics of microparticles after experimental pulmonary embolism. Thromb Res 2012; 130: 122-128.
55. Tamburrelli C, Crescente M, Izzi B, et al. Epoprostenol inhibits human platelet-leukocyte mixed conjugate and platelet microparticle formation in whole blood. Thromb Res 2011; 128: 446-451.
56. Freyssinet JM, Toti F. Membrane microparticle determination: at least seeing what's being sized. J Thromb Haemost 2010; 8: 311-314.
57. Yang C,Mwaikambo BR, Zhu T, et al. Lymphocytic microparticles inhibit angiogenesis by stimulating oxidative stress and negatively regulating VEGF-induced pathways. Am J Physiol Regul Integr Comp Physiol 2008; 294: R467-R476. (Pubitemid 351213752)
58. Lacroix R, Sabatier F, Mialhe A, et al. Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro. Blood 2007; 110: 2432-2439. (Pubitemid 47523164)
59. Brill A, Dashevsky O, Rivo J, et al. Platelet-derived microparticles induce angiogenesis and stimulate post-ischemic revascularization. Cardiovasc Res 2005; 67: 30-38. (Pubitemid 40798290)
60. Mezentsev A, Merks RM, O'Riordan E, et al. Endothelial microparticles affect angiogenesis in vitro: role of oxidative stress. Am J Physiol Heart Circ Physiol 2005; 289: H1106-H1114. (Pubitemid 41208953)
61. Leroyer AS, Ebrahimian TG, Cochain C, et al. Microparticles from ischemic muscle promotes postnatal vasculogenesis. Circulation 2009; 119: 2808-2817.
62. Ou ZJ, Chang FJ, Luo D, et al. Endothelium-derived microparticles inhibit angiogenesis in the heart and enhance the inhibitory effects of hypercholesterolemia on angiogenesis. Am J Physiol Endocrinol Metab 2011; 300: E661-E668.
63. Reich N, Beyer C, Gelse K, et al. Microparticles stimulate angiogenesis by inducing ELR+ CXC-chemokines in synovial fibroblasts. J Cell Mol Med 2011; 15: 756-762.